Stock Market

Biogen Soars 40% on Alzheimer’s Drug Trial. Mizuho Says the Stock Is a Buy.



Biogen


shares were soaring Wednesday after the biopharmaceutical company said that its experimental Alzheimer’s drug with Japan-based partner 


Eisai


showed promising results.

Guggenheim Securities analyst Yatin Suneja called the data “a new dawn for Alzheimer’s treatment.”


Share this news on your Fb,Twitter and Whatsapp

File source

Times News Express – Breaking News Updates – Latest News Headlines
Times News Express||USA NEWS||WORLD NEWS||CELEBRITY NEWS||POLITICS||TOP STORIES

Show More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
Close